Abstract
Tumor cell proliferation, de-differentiation, and progression depend on a complex combination of altered intracellular processes including cell cycle regulation, excessive growth factor pathway activation, and decreased apoptosis. Metabolites from these processes result in significant cellular oxidative stress that must be buffered to prevent permanent cell damage and cell death. Tumor cells depend on a complex set of respiratory pathways to generate the necessary energy as well as redox-sensitive pro-survival signaling pathways and factors to cope with and defend against the detrimental effects of oxidative stress. It has been hypothesized that redox-sensitive signaling factors such as thioredoxin reductase-1 (TR) and thioredoxin (TRX) may represent central pro-survival factors that would allow tumor cells to evade the damaging and potentially cytotoxic effects of endogenous and exogenous agents that induce oxidative stress. The overarching theme of this review is an extension of the hypothesis that tumor cells use these redox sensitive pro-survival signaling pathways/factors, which are up-regulated due to increased tumor cell respiration, to evade the cytotoxic effects of anticancer agents. These observations suggest that redox-sensitive signaling factors may be potential novel molecular targets for drug discovery.
Keywords: Molecular targets, redox signaling, anticancer drug resistance, thioredoxin
Current Pharmaceutical Design
Title: Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy
Volume: 13 Issue: 33
Author(s): J. Daniel Pennington, Kristi Muldoon Jacobs, Lunching Sun, Gil Bar-Sela, Mark Mishra and David Gius
Affiliation:
Keywords: Molecular targets, redox signaling, anticancer drug resistance, thioredoxin
Abstract: Tumor cell proliferation, de-differentiation, and progression depend on a complex combination of altered intracellular processes including cell cycle regulation, excessive growth factor pathway activation, and decreased apoptosis. Metabolites from these processes result in significant cellular oxidative stress that must be buffered to prevent permanent cell damage and cell death. Tumor cells depend on a complex set of respiratory pathways to generate the necessary energy as well as redox-sensitive pro-survival signaling pathways and factors to cope with and defend against the detrimental effects of oxidative stress. It has been hypothesized that redox-sensitive signaling factors such as thioredoxin reductase-1 (TR) and thioredoxin (TRX) may represent central pro-survival factors that would allow tumor cells to evade the damaging and potentially cytotoxic effects of endogenous and exogenous agents that induce oxidative stress. The overarching theme of this review is an extension of the hypothesis that tumor cells use these redox sensitive pro-survival signaling pathways/factors, which are up-regulated due to increased tumor cell respiration, to evade the cytotoxic effects of anticancer agents. These observations suggest that redox-sensitive signaling factors may be potential novel molecular targets for drug discovery.
Export Options
About this article
Cite this article as:
Pennington Daniel J., Jacobs Muldoon Kristi, Sun Lunching, Bar-Sela Gil, Mishra Mark and Gius David, Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy, Current Pharmaceutical Design 2007; 13 (33) . https://dx.doi.org/10.2174/138161207782360537
DOI https://dx.doi.org/10.2174/138161207782360537 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery In Vivo Human X-ray Investigation of Combined Polysaccharide Based Drug Delivery Systems Prepared for Colonic Delivery
Drug Delivery Letters Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature
Current Drug Targets Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine The Development of a PBPK Model for Atomoxetine Using Levels in Plasma, Saliva and Brain Extracellular Fluid in Patients with Normal and Deteriorated Kidney Function
CNS & Neurological Disorders - Drug Targets Plant Defensins and Defensin-Like Peptides - Biological Activities and Biotechnological Applications
Current Pharmaceutical Design Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Targeting Tumor-Related Immunosuppression for Cancer Immunotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets HMGB-1 as a Target for Inflammation Controlling
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Immune Modulation of Asian Folk Herbal Medicines and Related Chemical Components for Cancer Management
Current Medicinal Chemistry The Fabrication and Application of Bio-Functional Microspheres
Current Organic Chemistry Anti-Angiogenic Peptides for Cancer Therapeutics
Current Pharmaceutical Biotechnology Off-Label Trazodone Prescription: Evidence, Benefits and Risks
Current Pharmaceutical Design Mitochondria and Familial Predisposition to Breast Cancer
Current Genomics Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs
Current Cancer Drug Targets Meet Our Editorial Board Member:
Current Organic Chemistry Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine Natural Naphthoquinones with Great Importance in Medicinal Chemistry
Current Organic Synthesis